OpenNashEarnings

Cencora (COR) · Health Care

Cencora Q3 FY2026 earnings: summary, key numbers & outlook

Results filed 5 Aug 2026 · Quarter ended 30 Jun 2026

Slides (18 pages)Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Cencora closed its OneOncology acquisition in February 2026, deepening its specialty and oncology reach while GLP-1 volume and an oncology customer loss reshape U.S. demand.

Cencora completed the February 2026 acquisition of OneOncology, adding oncology practice relationships to its specialty business. U.S. demand grew on unit volume, including specialty products sold to health systems and physician practices and GLP-1 products for diabetes and weight loss. Offsetting this were lower brand manufacturer prices, the 2025 loss of an oncology customer and lower sales to its large mail order customer. In April 2026 it divested U.S. Consulting Services.

Management is steering toward a pharmaceutical-centric strategy built on specialty, digital transformation and talent, while exploring strategic alternatives for MWI Animal Health, Profarma and parts of PharmaLex. The tension is mix: GLP-1s carry lower gross margins, and the acquisition was financed with senior notes and term loans, raising interest costs. A new CFO and Chief Human Resources Officer have also joined the leadership team.

Slides & documents

Open the slide deck (PDF, 18 pages) ↗

Cencora Q3 FY2026 slide deck, page 1Cencora Q3 FY2026 slide deck, page 2Cencora Q3 FY2026 slide deck, page 3Cencora Q3 FY2026 slide deck, page 4Cencora Q3 FY2026 slide deck, page 5Cencora Q3 FY2026 slide deck, page 6

Showing the first 6 of 18 pages.

From Cencora investor relations

SEC filing

Key numbers

Revenue · GAAP
$84.8 billion

up 5.1% from a year ago

Diluted EPS · GAAP
$3.94

up from $3.52 a year ago

Adjusted diluted EPS · non-GAAP
$4.48

up 12.0% from $4.00

Net income attributable to Cencora · GAAP
$764M

Operating income · GAAP
$1.1B

up 29.1% from a year ago

Segment or metricValueChange
U.S. Healthcare Solutions revenue$74.9 billionup 4.9%
International Healthcare Solutions revenue$7.7 billionup 5.9%
Other revenue$2.3 billionup 6.9%
Where each number comes from
  • Revenue: “in its fiscal year 2026 third quarter ended June 30, 2026, revenue increased 5.1 percent year-over-year to $84.8 billion.”
  • Diluted EPS: “diluted earnings per share (EPS) was $3.94 for the third quarter of fiscal 2026 compared to $3.52 in the prior year third quarter.”
  • Adjusted diluted EPS: “Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased 12.0 percent to $4.48 in the fiscal third quarter from $4.00”
  • Net income attributable to Cencora: “Net Income Attributable to Cencora, Inc. | $764M | $869M Diluted Earnings Per Share | $3.94 | $4.48”
  • Operating income: “In the third quarter of fiscal 2026, operating income was $1.1 billion, an increase of 29.1 percent compared to the same quarter in the previous fiscal year”
  • U.S. Healthcare Solutions revenue: “U.S. Healthcare Solutions revenue was $74.9 billion in the third quarter of fiscal 2026, an increase of 4.9 percent compared to the same quarter of the previous fiscal year”
  • International Healthcare Solutions revenue: “International Healthcare Solutions revenue was $7.7 billion in the third quarter of fiscal 2026, an increase of 5.9 percent compared to the previous fiscal year’s third quarter”
  • Other revenue: “Revenue in Other was $2.3 billion in the third quarter of fiscal 2026, an increase of 6.9 percent compared to the previous fiscal year’s third quarter”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ3 FY2026vs year agovs last quarter
Revenue$84.8B+5.1%+8.2%
Operating income$1.1B+29.1%−2.0%
Net income$763.5M+11.1%−53.5%
Diluted EPS$3.94+11.9%−53.1%
Free cash flow$2.4B—+107.0%
Gross margin4.3%+0.7 pts−0.3 pts
Operating margin1.3%+0.2 pts−0.2 pts

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Adjusted diluted EPSfiscal 2026$17.75 to $17.95
Revenue growthfiscal 20264% to 6% growth
Adjusted operating income growthfiscal 202613% to 14% growth
Adjusted effective tax ratefiscal 2026~20%
Capital expendituresfiscal 2026~$900M

Key takeaways

  1. OneOncology deal deepens oncology and specialty reach

    The February 2026 acquisition lifted U.S. gross margin and added operating expenses. It extends Cencora's specialty position with physician practices.

  2. Specialty and GLP-1 volume drive U.S. demand

    U.S. growth came largely from unit volume, including specialty products to health systems and physician practices and GLP-1 products. GLP-1s carry lower gross profit margins.

  3. Customer losses are a partial drag

    The 2025 loss of an oncology customer and lower sales to the large mail order customer offset growth, as expected and consistent with the second quarter.

  4. Portfolio pruning continues with divestiture and reviews

    U.S. Consulting Services was divested in April 2026, and MWI Animal Health, Profarma and parts of PharmaLex are under strategic alternatives review.

  5. Buyback pulled forward; guidance raised

    Cencora repurchased $1 billion of shares, the amount it had expected to complete by end of calendar 2026, and raised its adjusted EPS range.

Charts

Revenue$84.8B+5.1% y/yQ3 FY26
Q4 FY24: $79.1B (worked out from the annual figure)Q4 24$79.1BQ1 FY25: $81.5BQ1 25$81.5BQ2 FY25: $75.5BQ2 25$75.5BQ3 FY25: $80.7BQ3 25$80.7BQ4 FY25: $83.7B (worked out from the annual figure)Q4 25$83.7BQ1 FY26: $85.9BQ1 26$85.9BQ2 FY26: $78.4BQ2 26$78.4BQ3 FY26: $84.8BQ3 26$84.8B

Fourth quarter worked out from the annual figure.

Data
Q4 FY24$79.1B *
Q1 FY25$81.5B
Q2 FY25$75.5B
Q3 FY25$80.7B
Q4 FY25$83.7B *
Q1 FY26$85.9B
Q2 FY26$78.4B
Q3 FY26$84.8B
Diluted EPS (GAAP)$3.94+11.9% y/yQ3 FY26
Q1 FY25: $2.50Q1 25$2.50Q2 FY25: $3.68Q2 25$3.68Q3 FY25: $3.52Q3 25$3.52Q1 FY26: $2.87Q1 26$2.87Q2 FY26: $8.40Q2 26$8.40Q3 FY26: $3.94Q3 26$3.94
Data
Q1 FY25$2.50
Q2 FY25$3.68
Q3 FY25$3.52
Q1 FY26$2.87
Q2 FY26$8.40
Q3 FY26$3.94

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin1.3%+0.2 pts y/yQ3 FY26
Q4 FY24: 0.2%Q4 240.2%Q1 FY25: 0.9%Q1 250.9%Q2 FY25: 1.4%Q2 251.4%Q3 FY25: 1.1%Q3 251.1%Q4 FY25: 0.0%Q4 250.0%Q1 FY26: 0.9%Q1 260.9%Q2 FY26: 1.5%Q2 261.5%Q3 FY26: 1.3%Q3 261.3%
Data
Q4 FY240.2%
Q1 FY250.9%
Q2 FY251.4%
Q3 FY251.1%
Q4 FY250.0%
Q1 FY260.9%
Q2 FY261.5%
Q3 FY261.3%
Free cash flow$2.4BQ3 FY26
Q4 FY24: $818.1MQ4 24$818.1MQ1 FY25: -$2.8BQ1 25-$2.8BQ2 FY25: $3.2BQ2 25$3.2BQ3 FY25: -$74.0MQ3 25-$74.0MQ4 FY25: $2.9BQ4 25$2.9BQ1 FY26: -$2.4BQ1 26-$2.4BQ2 FY26: $1.2BQ2 26$1.2BQ3 FY26: $2.4BQ3 26$2.4B
Data
Q4 FY24$818.1M
Q1 FY25-$2.8B
Q2 FY25$3.2B
Q3 FY25-$74.0M
Q4 FY25$2.9B
Q1 FY26-$2.4B
Q2 FY26$1.2B
Q3 FY26$2.4B

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

What did Cencora acquire and how did it affect the quarter?

Cencora acquired OneOncology in February 2026, which raised U.S. Healthcare Solutions gross margin and operating expenses and was financed partly with senior notes and term loans.

What is driving U.S. demand?

Unit volume growth, including specialty products sold to health systems and physician practices and GLP-1 products for diabetes and weight loss.

Which customers weighed on U.S. sales?

The 2025 loss of an oncology customer and lower sales to its large mail order customer, partly offset growth.

What is happening with non-core businesses?

U.S. Consulting Services was divested in April 2026, and MWI Animal Health, Profarma and certain PharmaLex components are being explored for strategic alternatives.

How did Cencora change its outlook?

It raised adjusted diluted EPS guidance to $17.75 to $17.95 from $17.70 to $17.90 and narrowed adjusted operating income growth to 13% to 14%, after repurchasing $1 billion of shares.